New oral combo shows promise for rare blood cancer
NCT ID NCT02844309
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a treatment plan using thalidomide, cyclophosphamide, and dexamethasone, followed by long-term thalidomide and prednisone, in 44 adults newly diagnosed with Waldenström macroglobulinemia, a rare blood cancer. The goal was to see how well the oral regimen controls the disease. Because patients need ongoing maintenance therapy, this approach aims to manage the condition rather than cure it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTRÖM MACROGLOBULINEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shuhua Yi
Tianjin, 300020, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug duo shows promise for rare blood cancer
- New PET tracer aims to spot hidden cancers without biopsy
- New hope for rare blood cancer: targeted drug shows promise in early trial
- New Two-Step transplant shows promise for blood cancer patients
- New drug targets Hard-to-Treat blood cancers in chinese trial
- New drug combo shows promise for blood cancer patients